Table 1 Patients characteristics

Age (years)

36

14-65

(14.7)

Male/Female (n, %)

28/16 (63.6%/36.3%)

Smokers

(male/female) (n, %)

8/28 (28.6%) and 3/16 (18.8%)

Non-Smokers

(male/female)

20/28 (71.4%) and 13/16 (81.3%)

BMI

30.23

20-45

(8.757)

No,pts with obesity (male/female)

7/28 (25%) and 4/16 (25%)

No.pts without obesity (male/female)

21/28 (75%) and 12/16 (75%)

Co-exististing conditions (n, %)

Asthma

15/44 (34%)

COPD

6/44 (13.6%)

IPF

1/44 (2.2%)

Lymphoma

5/44 (11.3%)

Diabetes

8/44 (18.1%)

Coronary Heart Disease

10/44 (22.7%)

Outcomes-days

   Duration of fever in hospital under treatment

2.45

1-4

(0.875)

   Days of Hospitalization

5.39

3-12

(1.781)

   Days under oseltamivir regimen

5.25

4-10

(1.014)

Adverse events (n, %)

Abnormal liver function

7/44 (15.9%)

Nausea, Diarrhea

4.5%

Vomiting

1.4%

Hypoxemia

1/44 (21.2%)

CRP

5.18

0.26-17.38

(5.123)

1.33

0.16-4.53

(1.01)

WBC

7.114

3.340-10.950

(2172.160)

6.806

3340-10950

(2021.6)

Fever

39.06

37-40

(0.834)

37.8

36.3-39.2

(0.77)

CR

0.9

0.5-1.30

(0.17)

0.8

5-1

(0.12)

UR

26.18

11-41

(7.469)

25.11

12-40

(7.127)

SGPT

24.48

10-138

(26.37)

27.80

9-136

(26.719)

SGOT

27.09

14-125

(22.941)

24.14

9-57

(12.22)

Spo₂ (FiO₂ 21%)

96.07

89-99

(2.3)

96.98

94-99

(1.248)

PO₂ (FiO₂21%)

81.23

53-113

(14.586)

87.66

67-113

(12.473)

Abnormalities on chest radiograph (n, %)

Local patchy shadowing

8/44 (18.1%)

6/44 (13.6%)

Ground-glass opacities

3/44 (6.8%)

2/44 (4.5%)

Interstitial abnormality

1/44 (2.2%)

1/44 (2.2%)